Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$12.66 +4.2%	$10.97	$3.98 ▼ $12.93	$1.93B	1.92	2.05 million shs	1.96 million shs
BHVN Biohaven	$13.46 +0.4%	$14.65	$12.79 ▼ $55.70	$1.37B	0.98	1.68 million shs	2.04 million shs
EWTX Edgewise Therapeutics	$13.39 +3.1%	$13.99	$10.60 ▼ $38.12	$1.41B	0.26	1.25 million shs	939,082 shs
UPXI Upexi	$6.66 +18.5%	$6.84	$1.90 ▼ $22.57	$595.14M	-0.52	3.39 million shs	9.86 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-0.41%	+11.37%	+2.79%	+30.79%	+171.81%
BHVN Biohaven	-8.81%	-8.65%	-3.35%	-31.16%	-65.50%
EWTX Edgewise Therapeutics	+2.44%	-4.56%	-6.14%	-12.76%	-21.03%
UPXI Upexi	-6.95%	+11.95%	+4.27%	-43.86%	+43.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	3.015 of 5 stars	1.4	2.0	4.2	2.6	2.5	0.6
BHVN Biohaven	3.1947 of 5 stars	4.5	1.0	0.0	2.2	2.5	0.6
EWTX Edgewise Therapeutics	2.0143 of 5 stars	3.5	2.0	0.0	2.4	1.7	0.0
UPXI Upexi	3.3795 of 5 stars	3.5	5.0	0.0	2.5	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.88	Moderate Buy	$12.38	-2.25% Downside
BHVN Biohaven	3.07	Buy	$54.54	305.19% Upside
EWTX Edgewise Therapeutics	2.90	Moderate Buy	$41.60	210.68% Upside
UPXI Upexi	3.00	Buy	$15.50	132.73% Upside

Current Analyst Ratings Breakdown

Latest UPXI, ADPT, EWTX, and BHVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $30.00
8/12/2025	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$63.00 ➝ $54.00
8/12/2025	BHVN Biohaven	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $52.00
8/12/2025	BHVN Biohaven	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $49.00
8/8/2025	EWTX Edgewise Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$48.00 ➝ $49.00
8/6/2025	ADPT Adaptive Biotechnologies	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$10.00 ➝ $14.00
8/6/2025	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00
8/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$13.00 ➝ $15.00
8/4/2025	UPXI Upexi	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
7/30/2025	EWTX Edgewise Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$46.00
6/30/2025	EWTX Edgewise Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	10.77	N/A	N/A	$1.37 per share	9.24
BHVN Biohaven	N/A	N/A	N/A	N/A	$4.19 per share	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.84 per share	N/A
UPXI Upexi	$26M	22.89	N/A	N/A	$6.24 per share	1.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.82	N/A	N/A	N/A	-59.07%	-60.93%	-23.03%	N/A
BHVN Biohaven	-$846.42M	-$9.36	N/A	N/A	N/A	N/A	-257.07%	-164.01%	8/14/2025 (Estimated)
EWTX Edgewise Therapeutics	-$133.81M	-$1.55	N/A	N/A	N/A	N/A	-32.81%	-31.13%	8/14/2025 (Estimated)
UPXI Upexi	-$23.66M	N/A	0.00	∞	N/A	-135.86%	-535.19%	-122.94%	9/29/2025 (Estimated)

Latest UPXI, ADPT, EWTX, and BHVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q1 2025	BHVN Biohaven	-$1.94	-$1.94	N/A	-$1.94	$0.41 million	N/A
8/7/2025	Q2 2025	EWTX Edgewise Therapeutics	-$0.42	-$0.34	+$0.08	-$0.34	N/A	N/A
8/5/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	-$0.17	+$0.07	-$0.17	$49.40 million	$49.94 million
5/16/2025	Q1 2025	UPXI Upexi	N/A	-$2.87	N/A	-$2.87	N/A	$3.16 million
5/12/2025	Q1 2025	BHVN Biohaven	-$1.67	-$2.17	-$0.50	-$2.17	$1.25 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
UPXI Upexi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.84	2.75
BHVN Biohaven	N/A	2.33	2.33
EWTX Edgewise Therapeutics	N/A	20.99	20.99
UPXI Upexi	0.31	0.37	0.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
BHVN Biohaven	88.78%
EWTX Edgewise Therapeutics	N/A
UPXI Upexi	5.68%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
BHVN Biohaven	14.60%
EWTX Edgewise Therapeutics	23.20%
UPXI Upexi	31.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	152.27 million	142.53 million	Optionable
BHVN Biohaven	239	102.11 million	87.21 million	Optionable
EWTX Edgewise Therapeutics	60	105.35 million	80.91 million	Optionable
UPXI Upexi	130	89.36 million	61.12 million	Optionable

UPXI, ADPT, EWTX, and BHVN Headlines

Recent News About These Companies

Upexi (NASDAQ:UPXI) Sees Unusually-High Trading Volume - Time to Buy?

2 hours ago | marketbeat.com

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Upexi, Inc. (NASDAQ: UPXI)

August 11 at 8:00 AM | prnewswire.com

Upexi (NASDAQ:UPXI) Shares Up 14.2% - Here's What Happened

August 9 at 1:00 PM | marketbeat.com

Crypto Currents: SEC eases staking rules as bitcoin miners pivot to AI

August 6, 2025 | msn.com

Alliance Global Partners Begins Coverage on Upexi (NASDAQ:UPXI)

August 6, 2025 | americanbankingnews.com

Upexi Surpasses 2 Million SOL in its Treasury

August 5, 2025 | taiwannews.com.twT

Solana Treasury Company Upexi Surpasses 2M in SOL Holdings

August 5, 2025 | coindesk.com

Upexi (NASDAQ:UPXI) Earns Buy Rating from Analysts at Alliance Global Partners

August 5, 2025 | marketbeat.com

Upexi, Inc. (NASDAQ:UPXI) Director Gene Salkind Buys 20,243 Shares

July 31, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 20,243 Shares of Stock

July 31, 2025 | insidertrades.com

Upexi (NASDAQ:UPXI) Stock Price Down 9.9% - What's Next?

July 31, 2025 | marketbeat.com

Upexi to Participate in Fireside Chat at Canaccord Genuity’s 45th Annual Growth Conference on August 12th-14th

July 30, 2025 | manilatimes.netM

Upexi Secures $500M Equity Deal to Buy More Solana Despite Stock Drop

July 30, 2025 | thecurrencyanalytics.comT

Upexi enters $500M equity line agreement

July 29, 2025 | msn.com

Upexi, Inc. Announces $500 Million Equity Line Agreement with A.G.P. to Accelerate the Growth of its Solana Treasury Strategy

July 29, 2025 | manilatimes.netM

Solana Treasury firm Upexi secures $500M to acquire more SOL

July 29, 2025 | msn.com

Upexi (NASDAQ:UPXI) Shares Gap Up - Here's Why

July 28, 2025 | marketbeat.com

Traders Buy Large Volume of Call Options on Upexi (NASDAQ:UPXI)

July 28, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Acquires 4,000 Shares of Stock

July 25, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) Director Purchases 11,000 Shares of Stock

July 25, 2025 | marketbeat.com

Insider Buying: Upexi, Inc. (NASDAQ:UPXI) CEO Buys 161,943 Shares of Stock

July 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPXI, ADPT, EWTX, and BHVN Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$12.66 +0.51 (+4.20%)

Closing price 04:00 PM Eastern

Extended Trading

$12.58 -0.08 (-0.64%)

As of 05:11 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Biohaven NYSE:BHVN

$13.46 +0.05 (+0.37%)

Closing price 03:59 PM Eastern

Extended Trading

$13.56 +0.10 (+0.74%)

As of 05:28 PM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Edgewise Therapeutics NASDAQ:EWTX

$13.39 +0.40 (+3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$13.22 -0.17 (-1.27%)

As of 04:10 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Upexi NASDAQ:UPXI

$6.66 +1.04 (+18.51%)

Closing price 04:00 PM Eastern

Extended Trading

$6.85 +0.19 (+2.90%)

As of 05:39 PM Eastern

Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time